Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Person › Details

Jean-Christophe Hyvert (Lonza Group AG (SWX: LONN))

Hyvert, Jean-Christophe (Lonza 202105 President Biologics and Cell + Gene)


Organisation Organisation Lonza Group AG (SWX: LONN)
  Today Lonza (Group)
  Group Lonza (Group)
Products Product contract manufacturing (biologicals)
  Product 2 cell and gene therapy manufacturing (CGT manufacturing)

Lonza Group AG. (5/6/21). "Press Release: Lonza Announces Expansion Plans for Next-Generation Mammalian Manufacturing Facilities in Visp (CH) and Portsmouth (US)". Basel.

> Lonza will invest approximately CHF 850 million to build two new state-of-the-art mammalian facilities and respond to customer demand regarding capacity, life cycle management and speed to market

> A new large-scale facility with the latest manufacturing technology in Visp (CH), will expand capacity by six 20,000L bioreactors to meet increasing market demand for biologics

> Small-scale, single-use technology facility planned for Portsmouth (US) to support customers scaling clinical to commercial manufacturing with capacity for up to eight 2,000L bioreactors

> The investment is supported by a strong pipeline and underlines Lonza’s continuing commitment to serving customers across modalities and scales

Quote from Pierre-Alain Ruffieux, CEO, Lonza:

“As we look at the biologics market, we see a combination of growth at pace coupled with continuing high customer demand. In recent months, the COVID-19 pandemic has placed the spotlight on supply chains and the critical role CDMOs play in ensuring an adequate supply of medicines. The expansion of both our large-scale and small-scale manufacturing capacity will ensure Lonza continues to deliver industry-leading contract manufacturing services that will support our customers’ needs in the medium and long term.”

Quote from Jean-Christophe Hyvert, President, Biologics and Cell & Gene, Lonza:

“At Lonza, we are focused on supporting our customers to achieve efficient, high-throughput production processes and flexible manufacturing solutions. Our customers’ needs range from the manufacture of small-to mid-volume products, such as innovative pharmaceuticals for rare diseases affecting smaller patient populations, to the large-scale commercial production of biologics. These expansions serve to strengthen our position as a critical partner in the development and manufacture of such medicines.”

Basel, Switzerland, 6 May 2021 – Lonza today announced significant investments to expand its mammalian drug substance manufacturing facilities in Visp (CH) and Portsmouth (US).

The expansion in Visp (CH) will see the development of a new large-scale mammalian drug substance manufacturing facility t expand capacity with six 20,000L bioreactors to meet increasing market demand in biologics. The new facility will have an area of approximately 27,500 m².

The investment will increase large-scale biologics manufacturing capacity to meet customer demand in the contract manufacturing space. The state-of-the-art, high throughput facility includes perfusion capabilities and is designed to support high titer processes and accommodate the next generation of mammalian biologics.

Designed to optimize energy efficiency and water use, the facility is expected to be completed in 2024 and will require an investment of approximately CHF 650 million. The expansion will complement the existing large-scale global network at Lonza sites in Tuas (SG), Portsmouth (US) and Porriño (ES).

In Portsmouth (US), a new next-generation facility supporting late-phase clinical and commercial development and manufacturing will add capacity for up to eight 2,000L single-use bioreactors over an area of 3,000m².

This CHF 200 million expansion will help meet the increasing market demand for small-to mid-scale mammalian-derived biologics and support the implementation of high titer and high throughput platform processes.

The facility is designed to support Phase 3 clinical and commercial small-to mid-volume products. It will include state-of-the-art technologies in perfusion, purification, and automation.

Combined with Lonza’s industry-leading services in process characterization and process validation, the facilitywill offer customers an optimized path through BLA to market as well as the flexibility to meet challenges in product forecasting during the initial years of product launch.

The facility is expected to be completed in 2023 and will complement the existing single-use network at Lonza sites in Hayward (US), Slough (UK), Tuas (SG) and Visp (CH).

Following previous investments in mammalian mid-scale capacity, development services and drug product services, the new investment reflects Lonza’s commitment to enabling customers to bring drugs to market faster, meet customers’ specific needs and offer end-to-end solutions across multiple modalities and scales.

Recruitment has already commenced for both of the new facilities. More than 300 new jobs will be created in Visp (CH), while 250 new positions will be recruited in Portsmouth (US), reinforcing Lonza’s commitment to the communities in which it operates.

About Lonza

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion. Find out more at

Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter

Lonza Contact Details

Dirk Oehlers
Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540

Victoria Morgan
Head of ExternalCommunications
Lonza Group Ltd
Tel +41 61 316 2283

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Lonza Group Ltd¦ Muenchensteinerstrasse 38 ¦CH-4002 Basel ¦Switzerland+41 61 316 81 11 ¦ ¦

Record changed: 2024-04-02


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Jean-Christophe Hyvert

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px

» top